Media Release

COPENHAGEN, Denmark; March 1, 2022

Genmab A/S (Nasdaq: GMAB) announced today that Birgitte Stephensen has been appointed to Chief Legal Officer and Chris Cozic has been appointed to Chief People Officer within the Genmab Executive Management Team and promoted to Executive Vice Presidents effective March 1, 2022. Birgitte Stephensen joined Genmab in 2002 and previously served as Genmab’s Senior Vice President, Intellectual Property Rights and Legal. Chris Cozic joined Genmab in 2017 and most recently served as Senior Vice President Global Human Resources. Birgitte and Chris both serve on the Executive Management Team with Genmab’s President and Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, Chief Medical Officer Dr. Tahi Ahmadi, and Chief Operating Officer Anthony Mancini.

Based in Genmab’s headquarters in Copenhagen, Denmark, Birgitte has extensive experience from both private practice and industry working with intellectual property and legal matters within the pharmaceutical and biotech field. In her tenure at Genmab, she has been instrumental in leading the company’s intellectual property rights and legal strategy. Birgitte passed the European Qualifying Examination as European Patent Attorney. She earned a Master of Science from the Danish University of Pharmaceutical Sciences.

Based in Genmab’s Princeton, U.S. office, Chris has extensive experience as a global human resource executive in strategic leadership, organization design, human resource management, policy development, employee relations, organizational development, and a heavy concentration in all aspects of corporate growth and expansion. Prior to joining Genmab, he held leadership roles in the biopharma and telecommunications industries. Chris received his bachelor’s degree in English and Communications from Quinnipiac University and also attained Senior and Global Professional Human Resource (SPHR and GPHR) certifications.

“Genmab is on an exciting journey towards becoming an integrated biotech innovation powerhouse bringing our own innovative medicines to patients. We have a world-class Executive Management Team and both Birgitte and Chris’ appointments further strengthen and elevate the critical work of their groups for our company,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

About Genmab
Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab’s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people’s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab’s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.

Contact:        
Marisol Peron, Senior Vice President, Global Investor Relations & Communications
T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:
Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo^®; HuMax^®; DuoBody^®; DuoBody in combination with the DuoBody logo^®; HexaBody^®; HexaBody in combination with the HexaBody logo^®; DuoHexaBody^® and HexElect^®.

Media Release no. 05
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark